The most recent short interest data has been released for the 02/28/2018 settlement date, which shows a 655,715 share decrease in total short interest for Momenta Pharmaceuticals Inc , to 4,539,415, a decrease of 12.62% since 02/15/2018. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.
Investors in Momenta Pharmaceuticals Inc saw new options begin trading this week, for the April 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MNTA options chain for the new April 20th contracts and identified one put and one call contract of particular interest.
This is the second generic Copaxone 40 mg/mL greenlighted by the U.S. Food and Drug Administration.
In recent trading, shares of Momenta Pharmaceuticals Inc have crossed above the average analyst 12-month target price of $15.50, changing hands for $15.75/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.
Levi & Korsinsky announces it has commenced an investigation of Momenta Pharmaceuticals, Inc.
This market is badly in need of some resets as it has been nearly straight up the first week of the year.
M281 data shows safety and tolerability with no serious adverse events
Targeting the initiation of a pivotal patient clinical trial in the first half of 2018
-- Targeting the initiation of a pivotal patient clinical trial in the first half of 2018 --
In recent trading, shares of Momenta Pharmaceuticals Inc have crossed above the average analyst 12-month target price of $14.00, changing hands for $14.10/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.
Investors in Momenta Pharmaceuticals Inc saw new options begin trading this week, for the January 2018 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MNTA options chain for the new January 2018 contracts and identified one put and one call contract of particular interest.
The most recent short interest data has been released for the 10/31/2017 settlement date, which shows a 699,664 share increase in total short interest for Momenta Pharmaceuticals Inc , to 7,483,025, an increase of 10.31% since 10/13/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.
State attorneys general led by Connecticut's George Jepsen said Tuesday that were planning to include Mylan president Rajiv Malik and Emcure Pharmaceuticals Ltd. executive Satish Mehta in an expanded complaint in the federal generic drug antitrust lawsuit.
The Cambridge, Mass.-based company and Mylan said that M834, a proposed biosimilar of Orencia (abatacept), did not achieve its primary pharmacokinetic endpoints in a Phase 1 study.
Investors in Momenta Pharmaceuticals Inc saw new options begin trading this week, for the June 2018 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 233 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
Investors in Momenta Pharmaceuticals Inc saw new options become available this week, for the November 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MNTA options chain for the new November 17th contracts and identified one put and one call contract of particular interest.
The pharmaceutical company on Oct. 3 said the FDA has approved its generic version of Teva's multiple sclerosis drug Copaxone.
